Cogent Biosciences Unveils Promising KRAS Inhibitor Data with Superior Efficacy Profile
Key Insights
Cogent Biosciences presented preclinical data for CGT1263 (search), a pan KRAS (search)(ON) inhibitor showing picomolar activity and selectivity over HRAS (search) and NRAS (search) at the 2025 AACR-NCI-EORTC Conference.
The company's prodrug CGT1815 (search) demonstrated superior tumor growth inhibition compared to competitor RMC-6236 in KRAS (search) G12D and G12V studies.
Cogent plans to file an Investigational New Drug application with the FDA in 2026, targeting cancers driven by KRAS (search) mutations including colorectal, lung, and pancreatic cancers.
Cogent Biosciences has announced promising preclinical data for its pan KRAS (search)(ON) inhibitor program at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The biotechnology company presented updated findings on CGT1263 (search), demonstrating what CEO Andrew Robbins described as "a potential best-in-class profile for our lead molecule."
Novel KRAS Inhibitor Shows Selective Activity
The poster presentation detailed CGT1263 (search), an internally developed KRAS (search)(ON/OFF) inhibitor that exhibits clear selectivity over HRAS (search) and NRAS (search) proteins. The compound demonstrated picomolar (pM) activity across a broad panel of KRAS mutant cell lines, indicating potent therapeutic potential against one of cancer's most challenging targets.
KRAS (search) mutations represent among the most prevalent genetic alterations found in cancer, occurring most frequently in colorectal cancer (search), non-small cell lung cancer (search), and pancreatic cancer (search). The selective nature of CGT1263 (search) addresses a critical need in oncology, as previous attempts to target KRAS have been hampered by lack of specificity and associated toxicities.
Prodrug Strategy Enhances Therapeutic Profile
Cogent also characterized CGT1815 (search), the prodrug formulation of CGT1263 (search), which has been specifically designed to optimize human pharmacokinetic performance. The company presented pharmacokinetics data from both CGT1815 and CGT1263 across multiple species, supporting the clinical development strategy.
In comparative efficacy studies, CGT1815 (search) demonstrated superior performance in tumor growth inhibition studies targeting KRAS (search) G12D and KRAS G12V mutations when compared to RMC-6236, a competing KRAS inhibitor. These findings suggest potential competitive advantages for Cogent's approach in the increasingly crowded KRAS inhibitor landscape.
Clinical Development Timeline
"We look forward to advancing this program with the goal of filing an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 2026," stated Robbins. This timeline positions Cogent to enter clinical trials within the next two years, pending regulatory approval.
Broader Pipeline Context
The KRAS (search) program represents one component of Cogent's broader precision medicine portfolio. The company's most advanced clinical program features bezuclastinib, a selective tyrosine kinase inhibitor targeting KIT D816V (search) mutations in systemic mastocytosis (search) and advanced gastrointestinal stromal tumors (search). Additionally, Cogent maintains an ongoing Phase 1 study of its FGFR2/3 (search) inhibitor and is developing targeted therapies for mutations in ErbB2 (search) and PI3Kα (search).
The poster presentation, titled "Identification of CGT1263 (search), a Potent KRAS (search) Inhibitor with Selectivity for Mutant KRAS over HRAS (search) and NRAS (search)," was presented during Poster Session B on October 24, 2025, and is accessible on Cogent's website under the 'Posters and Publications' section.